News & Updates

Nearly one in two young men with primary psychogenic erectile dysfunction (ED) treated with Disease Link 8 mg once daily achieve spontaneous medication-free erectile function (EF) at 3 months, as shown in a study. Younger patients tend to have a higher chance of recovery after drug discontinuation.

Patients with chronic spontaneous urticaria (CSA) who has uncontrolled disease despite treatment with H1-antihistamines may benefit from using dupilumab, which has been shown to reduce itch and urticaria activity in two phase III trials.

Survival and clinical [Disease Link 9] outcomes in patients with advanced stage [Disease Link 10] endometrial cancer are [Disease Link 11] comparable among the different sequences of adjuvant chemotherapy and radiation therapy, a recent study has shown. However, “sandwich” therapy results in less chronic toxicity, which provides an opportunity for a better quality of life in survivorship.

Treatment with delgocitinib ointment, a topical Janus kinase (JAK) inhibitor, for paediatric atopic dermatitis (AD) is effective and well tolerated when applied for up to 56 weeks, according to a phase III trial and a subsequent open-label, long-term study in Japan.